Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT + KarX-EC in Psychosis Associated With Alzheimer's Disease
NCT06947941Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in psychosis comparing Placebo with KarXT + KarX-EC Arm (2 arms). Primary endpoint: Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions at 14 weeks. Started Mar 2026; status: recruiting.
02
Drugs
xanomelineKarX-EC
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT06947941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947941.